Weight loss caused by common diabetes drug tied to 'anti-hunger' molecule in study

March 18 2024



Metformin 500mg tablets. Credit: public domain

An "anti-hunger" molecule produced after vigorous exercise is responsible for the moderate weight loss caused by the diabetes medication metformin, according to a new study in mice and humans. The molecule, lac-phe, was discovered by Stanford Medicine researchers in 2022.

The finding, made jointly by researchers at Stanford Medicine and at Harvard Medical School, further cements the critical role the molecule, called lac-phe, plays in metabolism, exercise and appetite. It may pave the way to a new class of weight loss drugs.

"Until now, the way metformin, which is prescribed to control blood sugar levels, also brings about weight loss has been unclear," said Jonathan Long, Ph.D., an assistant professor of pathology. "Now we know that it is acting through the same pathway as vigorous exercise to reduce hunger. Understanding how these pathways are controlled may lead to viable strategies to lower body mass and improve health in millions of people."

Long and Mark Benson, MD, Ph.D., an assistant professor of medicine at Harvard Medical School, are co-senior authors of the study, which was published in *Nature Metabolism*. Postdoctoral scholar Shuke Xiao, Ph.D., is the lead author of the study.

Many people with diabetes who are prescribed metformin lose around 2% to 3% of their body weight within the first year of starting the drug. Although this amount of weight loss is modest when compared with the 15% or more often seen by people taking semaglutide drugs such as Ozempic and Wegovy, the discoveries that led to those drugs also grew from observations of relatively minor, but reproducible, weight loss in people taking first-generation versions of the medications.

Post-workout appetite loss

When Long and colleagues at Baylor University discovered lac-phe in 2022, they were on the hunt for small molecules responsible for curtailing hunger after vigorous exercise. What they found was a Frankenbaby of lactate—a byproduct of muscle fatigue—and an amino acid called phenylalanine. They dubbed the hybrid molecule lac-phe and went on to show that it's not only more abundant after exercise but it also causes people (as well as mice and even racehorses) to feel less hungry immediately after a hard workout.

"There is an intimate connection between lac-phe production and lactate generation," Long said. "Once we understood this relationship, we started to think about other aspects of lactate metabolism."

Metformin was an obvious candidate because as it stimulates the breakdown of glucose (thus reducing blood sugar levels) it can trigger the generation of lactate.

The researchers found that obese laboratory mice given metformin had increased levels of lac-phe in their blood. They ate less than their peers and lost about 2 grams of body weight during the nine-day experiment.

Long and his colleagues also analyzed stored blood plasma samples from people with type 2 diabetes before and 12 weeks after they had begun taking metformin to control their blood sugar. They saw significant increases in the levels of lac-phe in people after metformin compared with their levels before treatment.

Finally, 79 participants in a large, multi-ethnic study of atherosclerosis who were also taking metformin had significantly higher levels of lac-phe circulating in their blood than those who were not taking the drug.

"It was nice to confirm our hunch experimentally," Long said. "The magnitude of effect of metformin on lac-phe production in mice was as

great as or greater than what we previously observed with exercise. If you give a mouse metformin at levels comparable to what we prescribe for humans, their lac-phe levels go through the roof and stay high for many hours."

Further research revealed that lac-phe is made by intestinal epithelial cells in the animals; blocking the ability of mice to make lac-phe erased the appetite suppression and weight loss previously observed.

Finally, a statistical analysis of the people in the atherosclerosis study who lost weight during the several-year study and follow-up period found a meaningful association between metformin use, lac-phe production and weight loss.

"The fact that metformin and sprint exercise affect your body weight through the same pathway is both weird and interesting," Long said. "And the involvement of the intestinal epithelial cells suggests a layer of gut-to-brain communication that deserves further exploration. Are there other signals involved?"

Long noted that, while semaglutide drugs are injected into the bloodstream, metformin is an oral drug that is already prescribed to millions of people. "These findings suggest there may be a way to optimize oral medications to affect these hunger and energy balance pathways to control body weight, cholesterol and blood pressure. I think what we're seeing now is just the beginning of new types of weight loss drugs."

Researchers from Beth Israel Deaconess Medical Center, Harbor-UCLA Medical Center, Cedars-Sinai Medical Center, Baylor College of Medicine, the University of Colorado, the University of Virginia and the Broad Institute contributed to the work.

More information: Tara TeSlaa, Metformin induces a Lac-Phe gut–brain signalling axis, *Nature Metabolism* (2024). DOI: 10.1038/s42255-024-01014-x , www.nature.com/articles/s42255-024-01014-x

Shuke Xiao et al, Lac-Phe mediates the effects of metformin on food intake and body weight, *Nature Metabolism* (2024). DOI: 10.1038/s42255-024-00999-9 , www.nature.com/articles/s42255-024-00999-9

Provided by Stanford University Medical Center